Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3595213 | 0.86 | CTSS (0.44) | CYP3A4 | |
| SCHEMBL3595493 | 0.82 | SCN9A (0.39) | SCN9ACNR1CNR2 | |
| SCHEMBL3591331 | 0.80 | CYP3A4 (0.33) | CYP3A4SCN9AALDH1A1TSHRHSD17B10 | |
| SCHEMBL3591330 | 0.78 | CYP3A4 (0.34) | CYP3A4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL3591329 | 0.76 | SYK (0.35) | CYP3A4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL3601469 | 0.73 | CYP3A4 (0.50) | CYP3A4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL3591335 | 0.71 | SYK (0.34) | CYP3A4SCN9AALDH1A1 | |
| SCHEMBL3590097 | 0.70 | CTSS (0.46) | CYP3A4 | |
| SCHEMBL3590094 | 0.67 | CTSS (0.37) | CYP3A4ALDH1A1TSHRHSD17B10 | |
| SCHEMBL3596145 | 0.67 | CTSS (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | CTSS, CTSZ, CTSF | CYP3A4 2233/4885SCN9A 4331/4885ALDH1A1 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.